SV investment has resulted in the approval of 24 novel therapeutics
SV News
15 September 2021Portfolio NewsPulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
3 August 2021SV NewsPaul LaViolette describes SV's investment focus
3 August 2021Portfolio NewsMestag Therapeutics Extends Seed Financing to $45 Million and Welcomes New Investors Forbion, GV (formerly Google Ventures) and Northpond Ventures
27 July 2021Portfolio NewsArtios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X
22 July 2021SV NewsInternational Biotech looks for M&A booster shot- 19 July 2021SV NewsSV Health Investors becomes a signatory of the Investing in Women Code signifying it’s commitment to contribute to improving female entrepreneurs’ access to tools, resources and finance.
13 July 2021Portfolio NewsBicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics
6 July 2021Portfolio NewsSitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement
22 June 2021Portfolio NewsImbria Pharmaceuticals Announces enrolment of the first 10 patients in IMPROVE-DiCE, an Exploratory Phase 2 Study Investigating the impact of IMB-1018972 on Cardiac Energetics, Metabolism and Function in Patients with Type 2 Diabetes
22 June 2021Portfolio NewsAlchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer
22 June 2021Portfolio NewsTRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases
9 June 2021Portfolio NewsCaraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders
